

30 June 2023
ASX Code: MXC
LSE Code: MXC

Change of Australian Registered Office and Principal Place of Business

A
S
X

R
E
L
E
A
S
E

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') advises that the Company's Australian registered office and principal place of business have changed, with immediate effect to the following:

Suite 1, 295 Rokeby Road
Subiaco WA 6008

Postal Address:

Suite 1, 295 Rokeby Road
Subiaco WA 6008

Telephone:

+61 8 6555 2950

Fax:

+61 8 6166 0261

-Ends-

Authorised for release by the board of directors, for further information please contact:

MGC Pharmaceuticals Ltd
Roby Zomer
CEO & Managing Director
+61 8 6382 3390
info@mgcpharma.co.uk

MGC Pharmaceuticals Ltd
Arron Canicais / Rowan Harland
Joint Company Secretaries
+61 8 6382 3390
info@mgcpharma.co.uk

UK Brokers
Peterhouse Capital
Charles Goodfellow / Lucy Williams / Duncan Vasey
+44 207 469 0930
cg@peterhousecap.com / lw@peterhousecap.com

UK Brokers
Oberon Capital
Aimee McCusker / Adam Pollock
+44 203 179 5300
aimeemccusker@oberoninvestments.com
adampollock@oberoninvestments.com

UK IR/PR Advisers
IFC Advisory
Graham Herring / Tim Metcalfe / Zach Cohen
+44 203 934 6630
mgcpharma@investor-focus.co.uk

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

LinkedIn: MGC Pharmaceuticals Ltd.

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

Instagram: @mgc_pharma